natgillin/translations-raw huggingface dataset:
Hepatobiliary disorders common increased alanine aminotransferase uncommon hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
Poremećaji jetre i žuči često povišena alanin aminotransferaza manje često hepatitis, citolitički hepatitis, hepatička steatoza, hepatomegalija, povišene transaminaze, povišena aspartat aminotransferaza, povišen bilirubin u krvi, povišena alkalna fosfataza u krvi, povišena gama-glutamiltransferaza
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir/ritonavir and patients should be monitored during treatment.
Prije početka terapije darunavirom/ritonavirom moraju se provesti odgovarajuća laboratorijska ispitivanja, te se bolesnike mora pratiti tijekom liječenja.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with boosted darunavir is required.
preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Istodobno uzimanje darunavira s niskom dozom ritonavira i kortikosteroida koji se metaboliziraju putem CYP3A (npr. flutikazonpropionat ili ostali kortikosteridi koji se primjenjuju inhaliranjem ili kortikosteroidi za nazalnu primjenu) mogu povećati rizik za razvoj sistemskih učinaka koritkosteroida, ukljućujući Cushingov sindrom i adrenalnu supresiju.
800/100 mg once daily N=343
800/100 mg jedanput na dan N=343
Ritonavir inhibits CYP3A, thereby increasing the plasma concentrations of darunavir considerably.
Ritonavir inhibiraju CYP3A te na taj način značajno povećavaju koncentracije darunavira u plazmi.
HIV-1 RNA < 50 copies/ml All patients
HIV-1 RNK < 50 kopija/ml Svi bolesnici
The Darunavir Krka 400 and 800 milligram tablets are used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and who have not used antiretroviral medicines before.
Tablete lijeka Darunavir Krka od 400 miligrama i 800 miligrama koriste se za liječenje odraslih i djece (u dobi od 3 godine i starije, tjelesne težine najmanje 40 kilograma) koji su zaraženi HIV-om i - prethodno nisu uzimali antiretrovirusne lijekove. - upojedinih bolesnika koji su već prije koristili antiretrovirusne lijekove (to će ustanoviti Vaš liječnik).
For information on cobicistat pharmacokinetic properties, consult the cobicistat Summary of Product Characteristics.
Za informacije o farmakokinetičkim svojstvima kobicistata, pogledajte sažetak opisa svojstava lijeka za kobicistat.
Concomitant use of boosted darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Istodobno uzimanje pojačanog darunavira i kortikosteroida koji se metaboliziraju putem CYP3A (npr. flutikazonpropionat ili ostali kortikosteridi koji se primjenjuju inhaliranjem ili kortikosteroidi za nazalnu primjenu) mogu povećati rizik za razvoj sistemskih učinaka koritkosteroida, ukljućujući Cushingov sindrom i adrenalnu supresiju.
Applicable to darunavir boosted with either ritonavir or cobicistat:
Primjenjivo na darunavir pojačan bilo ritonavirom bilo kobicistatom:
The evidence of efficacy of darunavir co-administered with ritonavir (600/100 mg twice daily) in ART-experienced patients is based on the 96 weeks analysis of the Phase III trial TITAN in ARTexperienced lopinavir naïve patients, on the 48 week analysis of the Phase III trial ODIN in ARTexperienced patients with no DRV-RAMs, and on the analyses of 96 weeks data from the Phase IIb trials POWER 1 and 2 in ART-experienced patients with high level of PI resistance.
Djelotvornost darunavira od 600 mg dvaput na dan primijenjenog istodobno sa 100 mg ritonavira dvaput na dan u bolesnika prethodno liječenih ART-om Dokaz djelotvornosti darunavira primijenjenog istodobno s ritonavirom (600/100 mg dvaput na dan) u bolesnika prethodno liječenih ART-om temelje se na analizi podataka dobivenih nakon 96 tjedana liječenja u ispitivanju TITAN faze III u bolesnika prethodno liječenih ART-om, a neliječenih lopinavirom, na analizi podataka dobivenih nakon 48 tjedana liječenja u ispitivanju ODIN faze III u bolesnika prethodno liječenih ART-om bez DRV RAM, i analizama podataka dobivenih nakon 96 tjedana u ispitivanjima POWER 1 i 2, faze IIb u bolesnika prethodno liječenih ART-om koji imaju visoki stupanj rezistencije na PI.
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11%
Indinavir 800 mg dvaput na dan indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11%
C-darunavir could be retrieved in faeces and urine, respectively.
C-darunavira može se naći u stolici, odnosno mokraći.
Darunavir KrKa 600 mg film coated tablets must not be chewed or crushed.
Darunavir Krka 600 mg filmom obložene tablete ne smiju se žvakati ili lomiti.
600 mg once daily efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction)
600 mg jedanput na dan efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz zbog inhibicije CYP3A) (↓ darunavir zbog indukcije CYP3A)
For patients with renal or hepatic impairment colchicine with boosted darunavir is contraindicated (see sections 4.3 and 4.4).
Za bolesnike s oštećenjem bubrega ili jetre kolhicin s pojačanim darunavirom je kontraindiciran (vidjeti dijelove 4.3 i 4.4).
Plasma concentrations of these medicinal products may be increased when co-administered with boosted darunavir, resulting in reduced serum cortisol concentrations.
Koncentracije ovih lijekova u plazmi mogu biti povišene, kada se primjenjuju istodobno s pojačanim darunavirom, dovodeći do sniženih koncentracija kortizola u serumu.
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
- Nakon što počnete uzimati lijekove za liječenje HIV infekcije dodatno uz oportunističke infekcije, također se mogu javiti autoimuni poremećaji (stanje u kojem imunosni sustav napada zdravo tjelesno tkivo).
darunavir/ritonavir N=12
Ishodi u 48. tjednu darunavir/ritonavir N=12
800 mg film-coated tablets:
800 mg filmom obložene tablete:
If parenteral midazolam is co-administered with darunavir co-administered with low dose ritonavir it may cause a large increase in the concentration of this benzodiazepine.
Ako se parenteralni midazolam istodobno primjenjuje s darunavirom istodobno primjenjenim s niskom dozom ritonavira to može izazvati velik porast koncentracija ovog benzodiazepina.
Co-administration of domperidone with boosted darunavir is contraindicated.
Istodobna primjena domperidona s pojačanim darunavirom je kontraindicirana.
No dose adjustment for darunavir /ritonavir is recommended.
Ne preporučuje se prilagodba doze darunavira/ritonavira.
Carbamazepine, clonazepam(to prevent seizures or to treat certain types of nerve pain) Colchicine (to treat gout or familial Mediterranean fever) Bosentan (to treat high blood pressure in the pulmonary circulation) Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam when used as injection, zoldipem (sedative agents)
(za liječenje depresije i tjeskobe) - maravirok (za liječenje HIV infekcije) - metadon (za liječenje ovisnosti o opijatima) - karbamazepin, klonazepam (za sprječavanje epileptičkih napadaja ili za liječenje određenih vrsta neurološke boli) - kolhicin (za liječenje gihta ili obiteljske mediteranske vrućice) - bosentan (za liječenje povišenog krvnog tlaka u plućnom krvotoku) - buspiron, klorazepat, diazepam, estazolam, flurazepam, midazolam kada se koristi u obliku injekcije, zolpidem (sedativi)
If concomitant use of boosted darunavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.
darunavira indicirana sa sildenafilom, vardenafilom ili tadalafilom, tada su preporučene sljedeće doze: jednokratna doza sildenafila ne prelazi 25 mg u 48 sati, jednokratna doza vardenafila ne prelazi 2,5 mg u 72 sata ili jednokratna doza tadalafila ne prelazi 10 mg u 72 sata.
Hepatobiliary disorders common hepatic enzyme increased uncommon hepatitis*, cytolytic hepatitis*
Poremećaji jetre i žuči često povišeni jetreni enzimi manje često hepatitis*, citolitički hepatitis*
Monitoring of renal function may be indicated when darunavir coadministered with low dose ritonavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Praćenje funkcije bubrega može biti indicirano kada se darunavir istodobno primijenjen s niskom dozom ritonavira daje u kombinaciji s tenofovirdizoproksiloom, posebno u bolesnika s podležećom sistemskom ili bubrežnom bolešću ili u bolesnika koji uzimaju nefrotoksične lijekove.
Skin and subcutaneous tissue disorders common rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus uncommon angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation rare
Poremećaji kože i potkožnog tkiva često osip (uključujući makularni, makulopapularni, papularni, eritematozni i osip koji svrbi), pruritus manje često angioedem, generalizirani osip, alergijski dermatitis, urtikarija, ekcem, eritem, hiperhidroza, noćna znojenja, alopecija, akne, suha koža, pigmentacija noktiju rijetko
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily.
Ukupni učinak ritonavira kao farmakokinetičkog pojačivača očitovao se u približno 14 puta većoj sistemskoj izloženosti darunaviru kada se primijeni jednokratna peroralna doza od 600 mg darunavira u kombinaciji sa 100 mg ritonavira dvaput na dan.
The maraviroc dose should be 150 mg twice daily when co-administered with darunavir with low dose ritonavir.
Doza maraviroka mora biti 150 mg dvaput na dan kada se primjenjuje istodobno s darunavirom s niskom dozom ritonavira bile su sukladne s podacima u anamnezi.
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with darunavir coadministered with low dose ritonavir.
Za lovastatin i simvastatin se očekuje značajno povišenje koncentracija u plazmi kada se primjenjuju istodobno s darunavirom primijenjenim s niskom dozom ritonavira. (inhibicija CYP3A)
Combination of rifampicin with darunavir with concomitant low dose ritonavir (see section 4.5).
Kombinacija rifampicina s darunavirom uz istodobno nisku dozu ritonavira (vidjeti dio 4.5).
600/100 mg twice daily N=296
600/100 mg dvaput na dan N=296
ODIN is a Phase III, randomised, open-label trial comparing darunavir/ritonavir 800/100 mg once daily versus darunavir/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA > 1,000 copies/ml.
ODIN je randomizirano, otvoreno ispitivanje faze III u kojem se darunavir/ritonavir od 800/100 mg jedanput na dan naspram darunavira/ritonavira od 600/100 mg dvaput na dan u bolesnika prethodno liječenih ART-om inficirani virusom HIV-1, a na probiru pri uključivanju u ispitivanje testiranje genotipa u tih bolesnika nije pokazalo mutacije povezane s rezistencijom na darunavir (tj. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V), dok je probir HIV-1 RNK u plazmi bio > 1000 kopija/ml.
Limited data is available in patients with HIV-1 clades other than B.
Za bolesnike s podtipovima HIV-1, osim podtipa B, dostupni su ograničeni podaci.
Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Ispitivanja su bila provedena s nižim dozama daruanvira od preporučanih ili s različitim režimom doziranja (vidjeti dio 4.2 Doziranje).
Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to < 18 years and weighing at least 40 kg without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Stoga se isto doziranje od jedanput na dan može primijeniti u adolescenata koji su prethodno liječeni u dobi od 12 do < 18 godina s težinom najmanje 40 kg, koji nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM)* a imaju plazmatsku HIV-1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
Silicified microcrystalline cellulose (Cellulose, microcrystalline; Silica, colloidal anhydrous) Magnesium stearate (E470b)
celuloza, mikrokristalična krospovidon hidroksipropilceluloza silicijev dioksid, koloidni, bezvodni silicificirana mikrokristalična celuloza (celuloza, mikrokristalična; silicijev dioksid, koloidni, bezvodni) magnezijev stearat (E470b)
Co-administration of boosted darunavir and amiodarone, bepridil, dronedarone, ivabradine, quinidine, or ranolazine is contraindicated (see section 4.3).
Istodobna primjena pojačanog darunavira i amiodarona, bepridila, dronedarona, ivabradina, kinidina ili ranolazina je kontraindicirana (vidjeti dio 4.3).
Bleeding in haemophiliac patients
Krvarenje u bolesnika s hemofilijom
Caution should be exercised when combining one of these antineoplastic agents with boosted darunavir.
Potreban je oprez kada se neki od tih antineoplastika kombinira s pojačanim darunavirom.
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, azole antifungals like clotrimazole).
Istodobna primjena darunavira i ritonavira i drugih lijekova koji inhibiraju CYP3A može smanjiti klirens darunavira i ritonavira te može rezultirati povišenjem koncentracija darunavira i ritonavira u plazmi (npr. indinavir, antifungalni azoli poput klotrimazola).
In the evening, take one 600 milligram Darunavir Krka tablet together with 100 milligram ritonavir.
- Navečer uzmite jednu tabletu lijeka Darunavir Krka od 600 miligrama zajedno sa 100 miligrama ritonavira.
The clinical trial data from ART-experienced patients (TITAN trial and the pooled analysis of the POWER 1, 2 and 3 and DUET 1 and 2 trials) showed that virologic response to darunavir coadministered with low dose ritonavir was decreased when 3 or more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) were present at baseline or when these mutations developed during treatment.
Podaci kliničkog ispitivanja provedenog među bolesnicima prethodno liječenih ARTom (ispitivanje TITAN i objedinjena analiza ispitivanja POWER 1, 2 i 3 te DUET 1 i 2) pokazali su da je virološki odgovor na darunavir primijenjen istodobno s niskom dozom ritonavira bio smanjen kada su na početku ispitivanja bile prisutne ili su se razvile tijekom liječenja 3 ili više mutacija, povezane s rezistencijom na darunavir (V11I, V32I, L33F, I47V, I50V, I54L ili M, T74P, L76V, I84V i L89V).
ANAESTHETIC Alfentanil
Alfentanil
With Baseline CD4+ cell count (x 10
S početnim brojem CD4+ stanica (x 10
≥ 30 kg-< 40 kg 675 mg darunavir /100 mg ritonavir once daily
≥ 30 kg-< 40 kg 675 mg darunavir /100 mg ritonavir jedanput na dan
with darunavir/cobicistat 800/150 mg
s darunavirom/kobicistatom 800/150 mg
Ritonavir may decrease plasma concentrations of voriconazole.
Ritonavir može sniziti koncentracije vorikonazola u plazmi. (indukcija CYP450 enzima)
Pravastatin 40 mg single dose pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63% an up to five-fold increase was seen in a limited subset of subjects
Pravastatin 40 mg jednokratna doza pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63% kod limitirane podskupine ispitanika primijećeno je povišenje do pet puta
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with boosted darunavir has not been established.
Nije ustanovljena sigurna i učinkovita doza sildenafila za liječenje pulmonalne arterijske hipertenzije s istodobnom primjenom pojačanog darunavira.
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, pancreatic enzymes increased uncommon pancreatitis acute
Poremećaji probavnog sustava vrlo često diarrhoea, nausea često povraćanje, bol u abdomenu, distenzija abdomena, dispepsija, flatulencija, povišeni enzimi pankreasa manje često akutni pankreatitis
Viruses isolated from patients on darunavir /ritonavir 600/100 mg twice daily experiencing virologic failure by rebound that were susceptible to tipranavir at baseline remained susceptible to tipranavir after treatment in the vast majority of cases.
Izolirani virusi u bolesnika na darunaviru/ritonaviru od 600/100 mg dvaput na dan u kojih je došlo virološkog neuspjeha zbog ponovnog porasta virusa u krvi, bili su osjetljivi na tipranavir na početku liječenja u velikoj većini su slučajeva ostali osjetljivi na tipranavir i nakon liječenja.
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
Darunavir/ritonavir se tijekom trudnoće smiju uzimati samo ako potencijalna korist opravdava potencijalni rizik.
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir with these antidepressants and a dose adjustment of the antidepressant may be needed.
Preporučuje se kliničko praćanje kada se ti antidepresivi primjenjuju istodobno s darunavirom s niskom dozom ritonavira, a može biti potrebna prilagodba doze antidepresiva.
How to store Darunavir Krka
Kako čuvati Darunavir Krka
A dose decrease may be needed for these drugs when co-administered with darunavir co-administered with low dose ritonavir.
Može biti potrebno smanjenje doze za te lijekove kada se primjenjuju istodobno s darunavirom s istodobno primijenjenom niskom dozom ritonavira.
Dexamethasone (systemic) Not studied.
Deksametazon (sistemski)
In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with darunavir co-administered with low dose ritonavir.
Nadalje, u kliničkim ispitivanjima s darunavirom primijećena je reaktivacija herpesa simpleksa i herpesa zostera uz istodobno liječenje s niskom dozom ritonavira.
Each film-coated tablet contains 400 mg or 800 mg darunavir.
Jedna filmom obložena tableta sadrži 400 mg ili 800 mg darunavira.
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the coadministered medicinal product.
Darunavir pojačan bilo ritonavirom bilo kobicistatom inhibira eliminaciju djelatnih tvari čiji klirens u velikoj mjeri ovisi o CYP3A, što dovodi do povećane izloženosti istodobno primijenjenom lijeku.
Darunavir may increase antifungal plasma concentrations and posaconazole, isavuconazole, itraconazole, or fluconazole may increase darunavir concentrations.
Darunavir može povećati koncentracije antifungika u plazmi, a posakonazol, izavukonazol, itrakonazol ili flukonazol mogu povećati koncentracije darunavira. (CYP3A i/ili P-gp inhibicija)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg)
Pedijatrijski bolesnici koji su prethodno liječeni ART-om (u dobi od 3 do 17 godina i težine najmanje 40 kg)
Caution should be exercised when combining one of these antineoplastic agents with darunavir with low dose ritonavir.
Potreban je oprez kada se neki od tih antineoplastika kombinira s darunavirom s niskom dozom ritonavira.
Darunavir co-administered with low dose ritonavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3).
Darunavir istodobno primijenjen s niskom dozom ritonavira ne smije se istodobno primijenjivati s proizvodima koji sadržavaju gospinu travu (Hypericum perforatum) (vidjeti dio 4.3).
Boosted darunavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3).
Pojačan darunavir ne smije se istodobno primjenjivati s proizvodima koji sadržavaju gospinu travu (Hypericum perforatum) (vidjeti dio 4.3).
Darunavir Krka might increase the risk for elevated potassium levels by drospirenone.
Darunavir Krka može povećati rizik od nastanka povišenih razina kalija radi drospirenona.
Twice daily dosing Weight
Doziranje dvaput na dan
ANTICONVULSANTS Phenobarbital Phenytoin
Fenobarbital Fenitoin
Concominant administration of boosted darunavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Istodobna primjena pojačanog darunavira i lurasidona, pimozida ili sertindola je kontraindicirana (vidjeti dio 4.3).
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered
Preporučuju se druge ili zamjenske kontracepcijske mjere kada se kontraceptivi na bazi estrogena primjenjuju istodobno s pojačanim darunavirom.
Co-administration is expected to reduce plasma concentrations of darunavir, ritonavir and cobicistat, which could lead to loss of therapeutic effect and possible development of resistance (see sections 4.4 and 4.5).
Očekuje se da će istodobna primjena sniziti koncentracije darunavira, ritonavira i kobicistata u plazmi, što može dovesti do gubitka terapijskog učinka i mogućeg razvoja rezistencije (vidjeti dijelove 4.4 i
Adverse reactions are listed by system organ class (SOC) and frequency category.
Nuspojave su navedene prema klasifikaciji organskih sustava i kategoriji učestalosti.
The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.
Preporučeni režim doziranja je 800 mg jedanput na dan s ritonavirom od 100 mg jedanput na dan uzeto s hranom.
Darunavir Krka 400mg film-coated tabletsareavailable in bottlescontaining 30 film-coated tablets (1 bottleof 30 film-coated tablets), 60 film-coated tablets (2 bottlesof 30 film-coated tablets), 90 filmcoated tablets (3 bottlesof 30 film-coated tablets)and 180 film-coated tablets (6 bottlesof 30 filmcoated tablets)in a box.
Darunavir Krka 400 mg filmom obložene tablete dostupne su u bočicama koje sadrže 30 filmom obloženih tableta (1 bočica s 30 filmom obloženih tableta), 60 filmom obloženih tableta (2 bočice s 30 filmom obloženih tableta), 90 filmom obloženih tableta (3 bočice s 30 filmom obloženih tableta) i 180 filmom obloženih tableta (6 bočica s 30 filmom obloženih tableta) u kutiji.
Voriconazole should not be combined with darunavir co-administered with low dose ritonavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.
Vorikonazol se ne smije kombinirati s darunavirom istodobno primijenjenim s niskom dozom ritonavira, osim ako se procijeni da omjer koristi i rizika opravdava primjenu vorikonazola.